IRulya Therapeutics (IRLA) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IRulya Therapeutics is the larger company by market cap ($432.4 million vs $415.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRLA | PROK |
|---|---|---|
| Share price | $39.88 | $1.04 |
| Market cap | $432.36M | $415.21M |
| 1-day change | -0.15% | -1.89% |
| YTD return | — | -53.57% |
| 1-year return | — | -52.51% |
| 5-year return | — | -89.49% |
| EPS (TTM) | $-162.79 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $893.00K |
| Revenue growth (YoY) | — | +1075.00% |
| Net income (latest FY) | $-83.98M | $-68.99M |
| Operating margin | — | -18477.83% |
| Net margin | — | -7725.20% |
| 52-week high | $910.00 | $2.65 |
| 52-week low | $15.10 | $0.87 |
| Distance from 52-week high | -95.62% | -60.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +90.90% | +525.00% |
| Average volume | 63.03K | 1.44M |
| Shares outstanding | 10.84M | 209.63M |
| Employees | 38 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About IRulya Therapeutics
IRLA stock →IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
IRLA vs PROK FAQ
Which is bigger, IRulya Therapeutics or ProKidney?
IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $415.21M for ProKidney (PROK).
Are IRulya Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.